Somayyeh Nasiripour

Dr. Somayyeh Nasiripour is a clinical pharmacist, researcher, and academic leader with extensive experience in clinical pharmacy education and translational cardiovascular research. She served as an Assistant Professor of Clinical Pharmacy at Iran University of Medical Sciences from 2014 to 2023, where she played an active role in curriculum development, mentoring students, and leading clinical research initiatives. With over a decade of academic and clinical experience, she has contributed to multiple clinical trials and published research in peer-reviewed, high-impact journals.

She earned her Ph.D. in Clinical Pharmacy from Tehran University of Medical Sciences in 2013, graduating with distinction and ranking second in the National Board of Pharmacotherapy Examination. Her doctoral research focused on the comparative effects of enoxaparin and heparin on inflammatory biomarkers in patients with ST-segment elevation myocardial infarction, strengthening the evidence base for cardiovascular pharmacotherapy.

Currently, Dr. Nasiripour is a postdoctoral fellow in Cellular and Integrative Physiology in San Antonio, where she integrates clinical insight with molecular and cellular research approaches. Her work aims to bridge bedside clinical practice with bench research, advancing translational medicine in cardiovascular disease. As a mentor, she is dedicated to cultivating scientific independence, analytical thinking, and research integrity in trainees, preparing them to become confident and impactful contributors to biomedical science.

Professional Background
Education
Honors
Research

Dr. Nasiripour’s research focuses on translational cardiovascular pharmacology, with an emphasis on the cellular and molecular mechanisms underlying cardiovascular disease. Her interests include inflammatory pathways in myocardial infarction, cardioprotective pharmacologic interventions, and biomarker-driven therapeutic strategies. She is particularly interested in bridging clinical pharmacotherapy with experimental models to improve therapeutic outcomes in cardiovascular patients.
Publications
1. Type 2 Diabetes and Alzheimer’s Disease: Molecular Mechanisms and Therapeutic Insights with a Focus on AnthocyaninMuhammad Sohail Khan, Ashfaq Ahmad, Somayyeh Nasiripour, Jean C Bopassa. Journal of Dementia and Alzheimer’s Disease 3 (1), 5 2026
1. Adenine accumulation in Endothelial Cells Induces Cardiotoxicity in Type 2 Diabetes. somayyeh Nasiripour, Muhammad S Khan, Ian Tamayo, Kumar Sharma, Jean Chrisostome Bopassa. Circulation 152 (Suppl_3), A4366146-A4366146.
2. Parkinson Disease Signaling Pathways Khan MS, Nasiripour S, Bopassa JC., Molecular Mechanisms, and Potential Therapeutic Strategies: A Comprehensive Review. *Int J Mol Sci*. 2025; 26(13):6416.
3. Mic60/Mitofilin Inhibitor, Miclxin, Induces Rat H9C2 Cardiomyoblast Death by Inhibiting the Removal of Damaged Mitochondria.Khan MS, Nasiripour S, Oyarzabal M, Banerjee S, Sharma K, Bhat MA, et al. 2025.
4. The Positive Effects of Colchicine Against Inflammatory Cytokines in Patients After Acute MI: A Randomized Clinical Trial Study. Banifatemeh SA, Hajahmadi M, Nasiripour S, Farasatinasab M, Deihim N, et al. The Positive Effects of Colchicine Against Inflammatory Cytokines in Patients After Acute MI: A Randomized Clinical Trial Study. *Zahedan J Res Med Sci*. 2025; 27(27).
5. Evaluation of Surgical Antibiotic Prophylaxis Guideline Adherence: A Cross-Sectional Study of Two Iranian Teaching Hospitals. Farasatinasab M, La'li A, Zibafard A, Khaleghian M, Nasiripour S, et al. Evaluation of Surgical Antibiotic Prophylaxis Guideline Adherence: A Cross-Sectional Study of Two Iranian Teaching Hospitals. *Arch Clin Infect Dis*. 2025; 20(2).
6. Colchicine with Infliximab Compared to Infliximab in Hospitalized Patients with COVID-19 Pneumonia: An Open-label Randomized Trial. M Yadollahzadeh, S Nasiripour, N Moradi Shahrbabak, N Rezaie et al . Coronaviruses 5 (1), 53-58 , 2024
7. Conducting Online Objective Structured Clinical Examination (OSCE) for Advanced Pharmacy Practice Experience (APPE) during COVID-19 pandemic: A Pilot Study in Iran university. M Shariatpanahi, S Nasiripour, M Farasatinasab, A Eshraghi. Quarterly of Iranian Distance Education Journal 5 (2), 92-98, 2023
8. A comparative study to assess the effectiveness of curcumin, mucosamin, and chlorhexidine in chemotherapy-induced oral mucositis. F Fardad, K Ghasemi, N Ansarinejad, N Khodakarim, S Nasiripour et al. Explore 2023; 19 (1), 65-70
9. An Open‐Label, Single‐Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin‐Induced Thrombocytopenia. M Farasatinasab, S Balouchzehi, OM Moghaddam, N Ansarinejad S Nasiripour. The Journal of Clinical Pharmacology 2022; 62 (11), 1379-1384
10. Cerebral Venous Sinus Thrombosis in a Young Body Builder Man With Androgen Use. M Farasatinasab, OM Moghaddam, S Nasiripour, M Hosseinzadeh Emam. Annals of Pharmacotherapy,2022; 56(9) 1079-1081
11. Effect of cannabis use on propofol requirement for ICU sedation. M Farasatinasab, S Nasiripour, A Aghabiklooei. Anaesthesiology Intensive Therapy 2022; 54 (1)
12. MicroRNAs and SARS-CoV-2 life cycle, pathogenesis, and mutations: biomarkers or therapeutic agents? F Abedi, R Rezaee, AW Hayes, S Nasiripour, G Karimi. Cell Cycle 2021; 20 (2), 143-153
13. Rivaroxaban as an alternative agent for heparin‐induced thrombocytopenia. M Farasatinasab, B Zarei, M Moghtadaei, S Nasiripour, N Ansarinejad. The Journal of Clinical Pharmacology 2020; 60 (10), 1362-1366
14. Can Colchicine as an Old Anti‐Inflammatory Agent Be Effective in COVID‐19?. M Farasatinasab, S Nasiripour,F Zamani. The Journal of Clinical Pharmacology 2020 ; 60(7): 828–829.
15. Preparation and evaluation of oxytocin SLNs as semi-finished product for nasal drops formulation. SM Alavi, S Ghaffari, S Nasiripour. Medical Science Journal of Islamic Azad University2020; 30 (1)
16. Beneficial effects of oral lactobacillus on pain severity in women suffering from endometriosis: A pilot placebo-controlled randomized clinical trial. S Khodaverdi, R Mohammadbeigi, M Khaledi, L Mesdaghinia, S Nasiripour. International Journal of Fertility & Sterility 2019; 13 (3), 178
17. Rituximab utilization evaluation with focused on available evidence for off-labeled indications. M Farasatinasab, S Aghabeigi, S Ramezaninejad, A Amouzegar, S Nasiripour. Journal of Pharmaceutical Care,2019; 14-20
18. Methotrexate infusion followed by uterine artery embolisation for the management of placental adhesive disorders: a case series. MR Babaei, MO Kian, Z Naderi, S Khodaverdi, Z Raoofi, F Javanmanesh, S Nasiripour. Clinical Radiology 2019; 74 (5), 378-383
19. Dabigatran as a treatment option for heparin‐induced thrombocytopenia. S Nasiripour, M Saif, M Farasatinasab, S Emami, A Amouzegar, A Basi. The Journal of Clinical Pharmacology 2019; 59 (1), 107-111
20. A case of ciprofloxacin-associated Achilles tendinitis. V Pirhajati Mahabadi, S Nasiripour, M Farasatinasab, S Nadjafi. Physiology and Pharmacology 2017; 21 (3), 172-174
21. A double blind randomized trial of efficacy and safety of 5% methimazole versus 2% hydroquinone in patients with melasma. N Atefi, E Behrangi, S Nasiripour, G Mehran, S Naeji, M Azizi, P Hassani,. Journal of Skin and Stem Cell 2017; 4 (2)
22. Neuroprotective Effects of Stiripentol on Oxygen-Glucose Deprivation in Primary Culture of Fetal Mice Cortical Neurons. N Fotovat Eskandari, G Vahabzadeh, F Golab, F Karimzadeh, S Nasiripour. The Neuroscience Journal of Shefaye Khatam 2017; 5 (1), 10-17
23. Premature Ejaculation Management. S Nasiripour, M Farasatinasab. Razi Journal of Medical Sciences 2017;23 (152), 65-76
24. The content of plasma selenium in early admitted septic patients. OM Moghaddam, MN Lahiji, A Moghaddas, M Farasatinasab, S Nasiripour. Journal of Research in Pharmacy Practice 2017;6 (1), 52
25. Drug-drug interactions: the importance of medication reconciliation. MJ Makiani, S Nasiripour, M Hosseini, A Mahbubi. Journal of research in pharmacy practice 2017; 6 (1), 61
26. Breast cancer epigenetics. B Abbasi, NA Nejad, F Fardad, S Nasiripour, T Ramim. Tehran University Medical Journal 2016; 74 (8), 535-544
27. Evaluation of Antimicrobial Susceptibility of Gram Negative Organisms by Minimum Inhibitory Concentration Method in Bandar Abbas, South of Iran. MJ Makiani, M Farasatinasab, S Nasiripour. Journal of Pharmaceutical Care, 2016; 40-43
28. Management of abnormal placenta implantation with methotrexate: a review of published data. M Farasatinasab, A Moghaddas, S Dashti-Khadivaki, Z Raoofi ,S Nasiripour. Gynecologic and Obstetric Investigation 2016; 81 (6), 481-496
29. Comparison of the Effects of Enoxaparin and Heparin on Inflammatory Biomarkers in Patients with ST-segment Elevated Myocardial Infarction: A prospective Open Label Pilot Clinical Trial. S Nasiripour, S Mousavi, A Mohagheghi, M Radfar, M Abdollahi. Iranian Journal of Pharmaceutical Research: IJPR 2014; 13 (2), 583
30. The effect of educating the use of spray by visual concept mapping method on the quality of life of children with asthma. P Bozorgzad, A Ebadi, M Moin, F Sarhangy, S Nasiripour, MA Soleimani. Iranian Journal of Allergy, Asthma and Immunology,2013; 63-67
31. Intra-articular hyaluronic acid injections Vs. dextrose prolotherapy in the treatment of osteoarthritic knee pain. SM Hashemi, F Madadi, S Razavi, M Nikooseresht, FH Kiyabi, S Nasiripour. Tehran University Medical Journal 2012; 70 (2)
32. Approach to Pandemic 2009 influenza: first report from a main referral hospital for Pandemic H1N1 influenza care in Iran . S Dashti-Khavidaki, H Khalili, F Gholamalipour, A Soudbakhsh, S Nasiripour. The Journal of Infection in Developing Countries 2010; 4 (10), 629-635
33. Gastric healing effect of melatonin against different gastroinvasive agents in cholestatic rats. Moezi L1, Nasiripoor S, Mohajer V, Maghsoodi M, Samini M. Pathophysiology 2010; 17 (1), 65-70
34. Serum vitamin D concentration in pandemic 2009 H1N1 influenza infected patients. H Khalili, S Nasiripour, M Etminiani-Esfahani. Journal of Diabetes and Metabolic Disorders 2010; 9, 19

Somayyeh Nasiripour

Education

Honors